The role of sildenafil in the treatment of stroke

Current Opinion in Investigational Drugs

Volumn 9, Issue 7, 2008, Pages 754-759

  Bednar, M M ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cyclic GMP; Neurogenesis; Neuroplasticity; Neurorestoration; Sildenafil; Stroke

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT; CHORIONIC GONADOTROPIN DERIVATIVE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; ERYTHROPOIETIN; ERYTHROPOIETIN DERIVATIVE; GLYCERYL TRINITRATE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MYELIN ASSOCIATED GLYCOPROTEIN; NITRATE; NITRIC OXIDE; NTX 265; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V INHIBITOR; PHOSPHOKINASE G; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN NOGO A; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SILDENAFIL; TADALAFIL; ZAPRINAST;

ANGIOGENESIS; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DENTATE GYRUS; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG DOSE TITRATION; DRUG MARKETING; DRUG MECHANISM; HIPPOCAMPUS; HUMAN; NERVE CELL PLASTICITY; NEUROPROTECTION; NEURORESTORATION; PATHOPHYSIOLOGY; REVIEW; STROKE; SUBGRANULAR ZONE; SUBVENTRICULAR ZONE; SYNAPTOGENESIS; TREATMENT OUTCOME; VASODILATATION;

ANIMALS; HUMANS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; STROKE; SULFONES; VASODILATOR AGENTS;

EID: 46749124422     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S et al: Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 115(5):e69-e171.
2. Stephenson J: Rising stroke rates spur efforts to identify risks, prevent disease. J Am Med Assoc (1998) 279(16):1239-1240.
3. Marler JR, Brott T, Broderick J, Kothari R, O'Donoghue M, Barsan W, Tomsick T, Spilker J, Miller R, Sauerbeck L, Jarrell J et al: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med (1995) 333(24):1581-1587. • A landmark trial demonstrating the efficacy of tissue plasminogen activator in acute stroke.
4. Goldstein LB: Acute ischemic stroke treatment in 2007. Circulation (2007) 116(13):1504-1514.
5. Garber K: Stroke treatment - light at the end of the tunnel? Nat Biotechnol (2007) 25(8):838-840.
6. Hurtado O, Pradillo JM, Alonso-Escolano D, Lorenzo P, Sobrino T, Castillo J, Lizasoain I, Moro MA: Neurorepair versus neuroprotection in stroke. Cerebrovasc Dis (2006) 21(Suppl 2):54-63.
7. Zhang RL, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, Zhang L, Chopp M: Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke (2002) 33(11):2675-2680.
8. Zhang L, Zhang RL, Wang Y, Zhang C, Zhang ZG, Meng H, Chopp M: Functional recovery in aged and young rats after embolic stroke: Treatment with a phosphodiesterase type 5 inhibitor. Stroke (2005) 36(4):847-852. • An important translational study documenting the capacity for aged animals to experience similar degrees of post-stroke improvement to that observed in young animals.
9. Jin K, Wang X, Xie L, Mao XO, Zhu W, Wang Y, Shen J, Mao Y, Banwait S, Greenberg DA: Evidence for stroke-induced neurogenesis in the human brain. Proc Natl Acad Sci USA (2006) 103(35):13198-13202. • This study builds upon earlier research in animals and humans by demonstrating the existence of post-stroke neurogenesis in humans.
10. Frankish H: Newborn neurons may help heal brain after stroke. Lancet Neurology (2006) 5(10):820.
11. Cramer SC, Riley JD: Neuroplasticity and brain repair after stroke. Curr Opin Neurol (2008) 21(1):76-82. • A timely review of post-stroke events and the therapeutic approaches being studied.
12. NCT00243880: Neuroprotection with statin therapy for acute recovery trial (Neu-START). NIH, Bethesda, MD, USA (2007). www.clinicaltrials.gov/ ct2/show/NCT00243880?term=stroke&type=Intr&intr=statin&rank=3
13. NCT00362414: β-hCG + erythropoietin in acute stroke (BETAS): NIH, Bethesda, MD, USA (2008). www.clinicaltrials.gov/ct/show/NCT00362414
14. Stem Cell Therapeutics Corp: Stem Cell Therapeutics announces receipt of no objection letter from Health Canada for its phase IIb clinical trial in stroke. Press Release (2007): December 04. www.marketwire.com/mw/ release.do?id=799216
15. Stem Cell Therapeutics Corp: Stem Cell Therapeutics Corp. announces positive interim results from its currently enrolling phase IIa clinical program for NTx™-265 in acute stroke. Press Release (2007): April 11. www.bioalberta.com/news_details1.asp?ID=54
16. Ehrenreich H, Bartels C, Sargin D, Stawicki S, Krampe H: Recombinant human erythropoietin in the treatment of human brain disease: Focus on cognition. J Renal Nutr (2008) 18(1):146-153.
17. 'Stem cell Trial of Recovery Enhancement After Stroke 2' (STEMS2): Pilot randomised placebo-controlled trial of granulocyte-colony stimulating factor in mobilising bone marrow stem cells in sub-acute stroke. Current Controlled Trials, London, UK (2008). www.controlled-trials.com/ cctspringview2/mrct/showTrial. html?mrid=240533&srch
18. Efficacy of nitric oxide in stroke trial: University of Nottingham, Nottingham, UK (2008): April 30. www.enos.ac.uk
19. NCT00452582: Sildenafil (Viagra) treatment of subacute ischemic stroke: NIH, Bethesda, MD, USA (2008). www.clinicaltrials.gov/ct/show/ NCT00452582
20. Altman J, Das GD: Autoradiographic and histologic evidence of postnatal neurogenesis in rats. J Comp Neurol (1965) 124(3):319-335. •• Seminal research demonstrating neurogenesis in the adult mammalian brain.
21. Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH: Neurogenesis in the adult human hippocampus. Nat Med (1998) 4(11):1313-1317. •• A classic study demonstrating the existence of adult human neurogenesis and the implications of this finding for understanding the extent of brain plasticity and the capacity for NR.
22. Cramer SC, Chopp M: Recovery recapitulates ontogeny. Trends Neurosci (2000) 23(6):265-271. •• An excellent early review comparing operant mechanisms responsible for embryologic CNS development and brain plasticity after stroke.
23. Seki T, Arai Y: Age-related production of new granule cells in the adult dentate gyrus. Neuroreport (1995) 6(18):2479-2482.
24. Zhang RL, Zhang Z, Zhang L, Wang Y, Zhang C, Chopp M: Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res (2006) 83(7):1213-1219.
25. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 327(6122):524-526. • A landmark paper demonstrating that endothelium-derived relaxing factor is NO.
26. Bredt DS, Snyder SH: Nitric oxide: A physiologic messenger molecule. Annu Rev Biochem (1994) 63:175-195.
27. Santacana M, Uttenthal LO, Bentura ML, Fernández AP, Serrano J, Martínez de Velasco J, Alonso D, Martínez-Murillo R, Rodrigo J: Expression of neuronal nitric oxide synthase during embryonic development of the rat cerebral cortex. Brain Res Dev Brain Res (1998) 111(2):205-222.
28. Zhang R, Zhang L, Zhang Z, Wang Y, Lu M, LaPointe M, Chopp M: A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol (2001) 50(5):602-611.
29. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci (1999) 22(9):391-397.
30. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res (1996) 8(2):47-52.
31. Jackson G, Gillies H, Osterloh I: Past, present, and future: A 7-year update of Viagra (sildenafil citrate). Int J Clin Pract (2005) 59(6):680-691. • A thorough review of the discovery and clinical experience with sildenafil.
32. Zhang R, Wang L, Zhang L, Chen J, Zhu Z, Zhang Z, Chopp M: Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ Res (2003) 92(3):308-313.
33. Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe M, Silver B, Chopp M: Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res (2006) 1118(1):192-198.
34. Silver B, Grover KM, Arcila X, Mitsias PD, Bowyer SM, Chopp M: Recovery in a patient with locked-in syndrome. Can J Neurol Sci (2006) 33(2):246-249.
35. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG et al: Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Stroke (2006) 37(6):1583- 1633.
36. Gillies HC, Roblin D, Jackson G: Coronary and systemic hemodynamic effects of sildenafil citrate: From basic science to clinical studies in patients with cardiovascular disease. Intl J Cardiol (2002) 86(2-3):131-141. • A comprehensive review of sildenafil relating its biochemical effects to its cardiovascular actions under physiological and pathophysiological conditions.
37. Kotera J, Fujishige K, Omori K: Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem (2000) 48(5):685-693.
38. Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, Omori K, Beavo JA, De Vente J: mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol (2003) 467(4):566-580.
39. Phillips BG, Kato M, Pesek CA, Winnicki M, Narkiewicz K, Davison D, Somers VK: Sympathetic activation by sildenafil. Circulation (2000) 102(25):3068-3073.
40. Kuroiwa T, Ting P, Martinez H, Klatzo I: The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol (1985) 68(2):122-129.
41. Li L, Jiang Q, Zhang L, Ding G, Zhang ZG, Li Q, Ewing JR, Lu M, Panda S, Ledbetter KA, Whitton P et al: Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res (2007) 1132(1):185-192.
42. Feng G, Maso S, Hideaki N: Phosphodiesterase 5 inhibitor, zaprinast, selectively increases cerebral blood flow in the ischemic penumbra in the rat brain. Neurological Res (2005) 27(6):638-643.
43. Kruuse C, Thomsen LL, Jacobsen TB, Olesen J: The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab (2002) 22(9):1124-1131.
44. Arnavaz A, Aurich A, Weibenborn K, Hartmann U, Emrich HM, Schneider U: Effect of sildenafil (Viagra) on cerebral blood flow velocity: A pilot study. Psychiatry Res Neuroimaging (2003) 122(3):207-209.
45. Diomedi M, Sallustio F, Rizzato B, Ferrante F, Leone G, Spera E, Scarfini M, Bernardi G: Sildenafil increases cerebrovascular reactivity: A transcranial Doppler study. Neurology (2005) 65(6):919-921.
46. Rosengarten B, Schermuly RT, Voswinckel R, Kohstall MG, Olschewski H, Weissmann N, Seeger W, Kaps M, Grimminger F, Ghofrani HA: Sildenafil improves dynamic vascular function in the brain: Studies in patients with pulmonary hypertension. Cerebrovasc Dis (2006) 21(3):194-200.
47. Lee JK, Kim JE, Sivula M, Strittmatter SM: Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci (2004) 24(27):6209-6217.
48. Wang L, Zhang ZG, Zhang RL, Chopp M: Activation of the P13-K/ Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J Cereb Blood Flow Metab (2005) 25(9):1150-1158.
49. Nakagawa S, Kim J, Lee R, Chen J, Fujioka T, Malberg J, Tsuji S, Duman RS: Localization of phosphorylated cAMP response element-binding protein in immature neurons of adult hippocampus. J Neurosci (2002) 22(22):9868-9876.
50. Chen J, Chopp M: Neurorestorative treatment of stroke: Cell and pharmacological approaches. NeuroRx (2006) 3(4):466-473. • A focused review of the role and inter-relationships of statins, erythropoietin, sildenafil/NO pathway and cell-based strategies as therapeutics in a new paradigm for stroke treatment.
51. Zhang Z, Klyachko V, Jackson MB: Blockade of phosphodiesterase type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release. J Physiol (2007) 584(1):137-147.
52. Carmichael ST: Cellular and molecular mechanisms of neural repair after stroke: Making waves. Ann Neurol (2006) 59(5):735-742 • A contemporary overview of the natural history of NR following stroke.
53. Hallbergson AF, Gnatenco C, Peterson DA: Neurogenesis and brain injury: Managing a renewable resource for repair. J Clin Invest (2003) 112(8):1128-1133. • An overview of adult neurogenesis, limitations for self repair, and physiological and pharmacological strategies for upregulation.